Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Catalyst Pharmaceuticals Inc.

www.catalystpharma.com

Latest From Triad Therapeutics Inc.

Kindred Spirits in Small Molecule Drug Discovery

Kinetix Pharmaceuticals hoped that a focus on a particular class of targets that shares structural similarities--the protein kinases--would yield small molecules for a variety of therapeutic areas. But in order to realize synergies between multiple research projects in protein kinases, the company couldn't partner the projects out to numerous pharmaceutical partners, each requiring exclusivity and confidentiality. After technological rival Vertex signed a multi-million dollar protein kinase development partnership with Novartis, Kinetix began to rethink its original business model. A $170 million acquisition offer by Amgen Inc. made strategic sense for the start-up.
BioPharmaceutical Research and Development Strategies

Accelerating Small Molecule Drug Discovery

Pharmaceutical companies face two giant risks; compound risk and target risk. So, despite an abundance of so-called validated targets emerging from genomics efforts, and novel high throughput tools for compound synthesis and screening that yield plenty of hits against each target, at the end of the day, pharmaceutical company productivity, as measured by approved drugs, remains low. Recently, several former big-pharma executives have founded private companies that hope to speed up the time it takes to come up with optimized small molecule leads. Each has staked out a particular niche where it thinks it can do better than big pharma at coming up with clinic-ready compounds. Kinetix Pharmaceuticals and Triad Pharmaceuticals hope to leverage their knowledge of particular gene families to come up with optimized leads; Enanta Pharmaceuticals hopes to morph peptides into drugs with a combinatorial approach to binding pharmacophores, and Sunesis hopes to tackle some of the targets that prove intractable for others, or in which only large molecules have been able to intervene. The new small molecule companies share a vision of drug discovery that is based on targets, rather than diseases.
BioPharmaceutical Strategy

Dealmaking Along the Faultlines

Big Pharma's valuations are depressed; biotech is red-hot. Alliance volumes have fallen, but average deal values are up. The valuation divide masks the subtler cracks dividing biotech's elite from a mass of undifferentiated technology providers. Drug companies are recognizing that basing discovery programs around new, proprietary targets is highly risky and lengthens R&D time. Targets themselves, absent optimized lead compounds, are increasingly commoditized. Therefore, companies who don't provide integrated discovery capabilities aren't going to get the high-value deals that will justify their current, sky-high valuations. Meanwhile, companies with integrated solutions must back up their promises of productivity enhancement with their own money--though they also get a richer share of the end proceeds.
BioPharmaceutical Strategy

Triad Therapeutics Inc.

Triad Therapeutics Inc. hopes to accelerate the drug discovery process through the use of its IOPE technology, which it claims significantly accelerates the discovery of nanomolar-affinity hits over those obtained with other currently available technologies. IOPE exploits NMR spectroscopy to map key structural elements among the members of individual classes of enzymes and then uses the data to design libraries of compounds biased to bind to targets of the class, in effect starting the medicinal chemistry process with a compound that is much closer to a development lead.
BioPharmaceutical Business Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Musculoskeletal & Connective Tissue Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Catalyst Pharmaceutical Partners Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Catalyst Pharmaceuticals Inc.
  • Senior Management
  • Patrick J McEnany, Chmn., Pres. & CEO
    Alicia Grande, VP, CFO & Treasurer
    Steven R Miller, PhD, COO & CSO
    Paul J Merrigan, Chief Commercial Officer
    Gary Ingentio, MD, PhD, CMO
  • Contact Info
  • Catalyst Pharmaceuticals Inc.
    Phone: (305) 529-2522
    355 Alhambra Circle
    Ste. 1500
    Coral Gables, FL 33134
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register